Grants for Unrestricted - Science and Technology

The "Carbon Management" grant, offered by the Department of Energy, provides $78.4 million in funding for U.S. organizations to develop and test technologies for capturing, removing, converting, and storing carbon to combat climate change, with applications due by October 14, 2024.

This grant provides funding for research and technology development in weather and atmospheric dynamics, aimed at advancing our understanding of Earth and space sciences.

This grant provides funding to colleges and universities to improve undergraduate STEM education through innovative teaching practices, curriculum development, and initiatives that promote diversity and institutional transformation.

The FY24 LCRP Translational Research Award mechanism supports advanced translational research that will foster transformation of promising ideas in lung cancer into clinical applications. Translational research may be defined as an integration of basic science and clinical observations. Observations that drive a research idea may originate from a laboratory discovery, population-based studies, or a clinicians firsthand knowledge of patient care. The ultimate goal of translational research is to move a concept or observation forward into clinical application. However, Principal Investigators (PIs) should not view translational research as a one-way continuum from bench to bedside but can include a reciprocal flow of ideas and information between basic science and clinical science (bench to bedside and/or bedside to bench). Research applications only in the area of mesothelioma will not be accepted. This mechanism is intended to fund a broad range of translational studies with two different funding levels. The following are general examples, although not all-inclusive, of the type of research projects that would be appropriate to propose under the current program announcement:Funding Level 1: Advanced preclinical studies aimed at translating results from animal studies to applications with human samples/cohorts (The Translational Research Award is not intended to support initial mechanistic studies of a new target.) Late-stage preclinical work leading to/preparing for a clinical trial, e.g., Investigational New Drug (IND) application submission Correlative studies that are associated with an open/ongoing or completed clinical trial, e.g., projects that utilize biospecimens from clinical trials to improve clinical management of lung cancer and/or define new areas of research Projects that develop endpoints for clinical trialsFunding Level 2 Pilot clinical trials where limited clinical testing (e.g., small sample size) of a novel intervention is necessary to inform the next step in the continuum of translational researchPreliminary lung cancer relevant data to support the feasibility of the research hypotheses and research approaches are required.

The Patient-Centered Outcomes and Survivorship Award supports high-risk, high-reward research studies that span the spectrum of behavioral health science, survivorship, health outcomes and comparative effectiveness research, including quality of life, symptom and side effect management, resilience, co-morbid conditions, and examining the physical, psychological, social, and economic effects of lung cancer among patients and their families.The overall intent of the FY24 LCRP Patient-Centered Outcomes and Survivorship Award is to promote evidence-based and patient-centered approaches to improve health and lung cancer related outcomes and enhance the patient experience in defined populations. Research studies may include, but are not limited to:Studies to examine and improve quality of life, decision-making, and symptom and side effect management (e.g., toxicity of treatment, palliative/supportive care, psychological distress and anxiety).Studies to investigate the impact of prevention, diagnostics, treatment, or health care delivery approaches on health outcomes.Studies to assess the relationship(s) between behavioral, cognitive, and/or social functioning in relation to lung cancer detection, initiation, progression, treatment, and rehabilitation.Studies into the psychological health and well-being of those affected by lung cancer (e.g., patients, family members).Development and testing for efficacy of lifestyle interventions and symptom management approaches to minimize disease risk and maximize quality of life.Key aspects of this award mechanism are:Impact: The Patient-Centered Outcomes and Survivorship Award is intended to support research that demonstrates the potential to have a major impact on patient outcomes. Research should challenge paradigms with respect to impact on patient care and outcomes. Proposed projects may include translational or clinical research, including pilot clinical trials. Impactful research will accelerate the movement of promising ideas into clinical applications, generate knowledge to improve clinical guidelines, or significantly advance behavioral, cognitive, and/or social functioning related to the target population.Study Design: Applications should clearly articulate the chosen design of the study. Basic studies should demonstrate research strategy, feasibility, and how the study relates to the human experience with lung cancer. Studies entailing retrospective or prospective recruitment should define the type of architecture of the study (e.g., descriptive, correlational, field experimental, meta-analyses). Study populations should be defined. The rationale should support the chosen study design with statistical evaluation to back the design. Questionnaires should be described in sufficient detail to justify interpretation of potential results.Preliminary Data: The Patient-Centered Outcomes and Survivorship Award requires preliminary data for all studies that propose the active (prospective) recruitment of human subjects. Studies not proposing active recruitment of human subjects are not required to present preliminary data but should be supported by sound reasoning and relevant literature.Patient Advocate Participation: Applications to the Patient-Centered Outcomes and Survivorship Award funding opportunity are encouraged to include a patient advocate. As part of the research team, the patient advocate would assist in the development of the research question, project design, oversight, recruitment, and evaluation, as well as other significant aspects of the proposed project. The patient advocate will be a person with a history of lung cancer diagnosis. As a lay representative, the patient advocate should be active in a cancer advocacy organization. Interactions with other team members should be well integrated and ongoing, not limited to attending seminars and semi-annual meetings. The role of the patient advocate should be focused on providing objective input on the research and its potential impact for individuals with or at risk for lung cancer.

The DoD Kidney Cancer, Translational Research Partnership Award is a funding opportunity designed to support collaborative research projects between clinicians and scientists, with the aim of accelerating the development and application of innovative ideas in kidney cancer treatment and care, particularly those relevant to active-duty Service Members, Veterans, and the American public.

U.S. Embassy Bern invites proposals for programs that strengthen cultural ties between the United States and Switzerland or Liechtenstein through cultural and exchange programming that highlights shared values and promotes bilateral cooperation and dialogue. All programs must include an American cultural element, or connection with (a) U.S. expert/s, organization/s, or institution/s in a specific field that will promote increased understanding of U.S. policy and perspectives. The PDS Small Grants Program is open to applications from Swiss, Liechtenstein, and U.S. organizations and individuals. We especially encourage and will prioritize applications from alumni of U.S. State Department Exchange Programs who are residents of Switzerland or Liechtenstein. Priority Program Areas: 1. Recognizing and countering disinformation and misinformation 2. Diversity, equity, inclusion, and accessibility, with a special focus on: 2.1. Women and girls, in all their diversity, in STEAM fields 2. 2.Increasing visibility, equity, inclusion, and accessibility of underrepresented groups in Switzerland and Liechtenstein, including immigrants, migrants, refugees, and asylees 3. Promoting mobility and knowledge transfer of apprenticeships between Switzerland/Liechtenstein and the United States 4. Strengthening entrepreneurship and economic collaboration between the United States and Switzerland with an emphasis on emerging and women entrepreneurs and business students Participants and Audiences: 1. Swiss and Liechtenstein residents 2. Underrepresented groups 3. Swiss and Liechtenstein youth aged 16 to 25 4. Emerging and established professionals and leaders in the priority program areas mentioned above Applicants should read the full description of the statement, attached here or on our website: https://ch.usembassy.gov/embassy/jobs/proposals/

The grant titled "ROSES 2024: C.27 Lucy in the L4 Trojans Participating Scientist Program" is a funding opportunity by NASA's Science Mission Directorate for research and technology in space and Earth sciences, with a specific focus on the Lucy in the L4 Trojans project, and it invites proposals from various types of organizations, both domestic and foreign.

Bipartisan Infrastructure Law (BIL) - Clean Fuels Products Shot: Supporting Carbon Utilization Products via Electrochemical Conversion and Refinery and Petrochemical Facilities Retrofitting The Office of Fossil Energy and Carbon Management (FECM) in collaboration with the National Energy Technology Laboratory (NETL) is issuing this Funding Opportunity Announcement (FOA). Awards made under this FOA will be funded, in whole or in part, with funds appropriated by the Infrastructure Investment and Jobs Act, more commonly known as the Bipartisan Infrastructure Law (BIL). The activities to be funded under this Funding Opportunity Announcement support BIL Section 40302. Research and Development funded under this Funding Opportunity Announcement will support the Departments Clean Fuels Products Shots initiative, which was established to support the national goal of achieving net-zero emissions by 2050 by developing the sustainable feedstocks and conversion technologies necessary to produce crucial fuels, materials, and carbon-based products that are better for the environment than current petroleum-derived components. It aims to meet projected 2050 net-zero emissions demands for 100 percent of aviation fuel; 50 percent of maritime, rail, and off-road fuel; and 50 percent of carbon-based chemicals by using sustainable carbon resources. Modification 000001: The purpose of this modification is to update wording within the Topic Area descriptions to clarify the Funding Opportunity Announcement does not restrict conversion of carbon oxides, change instances of "CO2" to "carbon" throughout the Funding Opportunity Announcement, and clarify the medium-term test requirement for Topic Area 1.

The FY24 KCRP Postdoctoral and Clinical Fellowship Award supports recent doctoral or medical school graduates in pursuit of innovative, high-impact kidney cancer research during their postdoctoral and/or clinical fellowship and allows them to obtain the necessary experience for an independent career as a leader in kidney cancer research. Applicants must demonstrate that the proposed research has high potential to lead to, or make, significant advancements in kidney cancer research and/or patient care. Applicants for this award must also exhibit a strong desire to pursue a career in kidney cancer research, with clear evidence for a researcher development plan that will lead to a successful independent career in kidney cancer. The critical components of this award mechanism are: Impact: Research supported by the FY24 KCRP Postdoctoral and Clinical Fellowship Award will have the potential for a major impact and accelerate progress toward ending kidney cancer. The impact may be short term or long term, but must move beyond an incremental advance. Applications are expected to identify the kidney cancer patients or at-risk individuals who would ultimately benefit from the proposed research. Research Strategy: The research proposed as part of the Postdoctoral and Clinical Fellowship Award must have high potential to lead to or make breakthroughs in kidney cancer. The scope of the research may include innovative, high-risk/high-reward research in the early stages of idea development or research already supported by preliminary data with the potential to make significant advancements toward clinical translation. The research strategy should demonstrate sound rationale, logical reasoning, and, if available, preliminary data. The proposed research should show evidence of rigorous experimental design, sufficient experimental details, appropriate controls, a statistical plan, and consideration of pitfalls and alternatives. Principal Investigator (PI): Under this award mechanism, the postdoctoral or clinical fellow is considered the PI and, as such, is expected to write the project narrative, researcher development plan, and other application components, with appropriate guidance from the mentor. While the PI is not required to have previous experience in kidney cancer research, the proposed project and researcher development plan must focus on kidney cancer. Applications must emphasize the PIs potential for success in becoming an independent kidney cancer researcher based on their qualifications, achievements/honors (including first-author publications and funding), and letters of recommendation. Mentor: The mentor (or co-mentor, if applicable) must possess the appropriate experience in kidney cancer research and/or patient care, to include recent publications and a record of active funding, and clearly demonstrate a commitment to guiding the PIs research and development as a researcher. If the mentor is not an experienced kidney cancer researcher, then formal co mentorship by an established kidney cancer researcher is required. The application must include information about the mentors experience in conducting innovative research and how they intend to support the PIs endeavors in kidney cancer. Mentorship by an investigator without an established record of mentoring pre- and/or postdoctoral trainees may be offset by the overall strength of the researcher development plan. Researcher Development Plan: Applications must provide details on the suitability of the PIs overall researcher development plan for attaining the goals of this award mechanism. Applications must elaborate on the qualities of the research environment in which the candidate will work, provide details on the individualized kidney cancer-focused researcher development plan, and describe how it will facilitate the PIs career development as an independent, innovative kidney cancer researcher. A multidisciplinary research approach to kidney cancer is highly encouraged, but not required; however, if there are multidisciplinary aspects, they should be clearly outlined in the application. Organizational-Level Emphasis: The following areas of emphasis are broadly applicable to many CDMRP programs, not just the KCRP. Investigators are encouraged to consider addressing these areas in their applications if doing so is appropriate for their line of research, addresses the FY24 KCRP strategic priorities and/or focus areas described in Section II.A.1 and Section II.A.2. Nuclear Medicine: Innovative research involving nuclear medicine and related techniques to support early diagnosis, more effective treatment, and improved health outcomes of active-duty Service Members and their Families is encouraged. Such research could improve diagnostic and targeted treatment capabilities through noninvasive techniques and may drive the development of precision imaging and advanced targeted therapies. Womens Health: CDMRP encourages research on health areas and conditions that affect women uniquely, disproportionately, or differently from men, including studies analyzing sex as a biological variable. Such research should relate anticipated project findings to improvements in women's health outcomes and/or advancing knowledge for women's health. Metastatic Cancer Task Force: A congressionally mandated Metastatic Cancer Task Force was formed with the purpose of identifying ways to help accelerate clinical and translational research aimed at extending the lives of advanced state and recurrent patients. As a member of the Metastatic Cancer Task Force, CDMRP encourages applicants to review the recommendations (https://health.mil/Reference-Center/Congressional Testimonies/2018/05/03/Metastatic-Cancer-Research) and submit research ideas to address these recommendations provided they are within the limitations of this funding opportunity and fit within the FY24 KCRP priorities. Rigorous Study Design: All projects should adhere to a core set of standards for rigorous study design and reporting to maximize the reproducibility and translational potential of clinical and preclinical research. The standards are described in SC Landis et al., 2012, A call for transparent reporting to optimize the predictive value of preclinical research, Nature 490:187-191 (https://www.nature.com/nature/journal/v490/n7419/full/nature11556.html). While these standards are written for preclinical studies, the basic principles of randomization, blinding, sample-size estimation, and data handling derive from well-established best practices in clinical studies. Military Service Involvement: Applications from investigators within the military services and applications involving multidisciplinary collaborations among academia, industry, the military services, the U.S. Department of Veterans Affairs (VA), and other federal government agencies are highly encouraged. These relationships can leverage knowledge, infrastructure, and access to unique clinical populations that the collaborators bring to the research effort, ultimately advancing research that is of significance to Service Members, Veterans, and/or their Families. If the proposed research relies on access to unique resources or databases, the application must describe the access at the time of submission and include a plan for maintaining access as needed throughout the proposed research. Research involving human subjects and human anatomical substances is permitted; however, clinical trials are not allowed under this program announcement. A clinical trial is defined in the Code of Federal Regulations, Title 45, Part 46.102 (45 CFR 46.102) as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include a placebo or another control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes. Studies that do not seek to measure safety, effectiveness, and/or efficacy outcome(s) of an intervention are not considered clinical trials. For the purposes of this funding opportunity, research that meets the definition of a clinical trial is distinct from clinical research. Clinical research encompasses research with human data, human specimens, and/or interaction with human subjects. Clinical research is observational in nature and includes: (1) Research conducted with human subjects and/or material of human origin such as data, specimens, and cognitive phenomena for which an investigator (or co-investigator) does not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention. Research meeting this definition may include but is not limited to: (a) mechanisms of human disease, (b) diagnostic or detection studies (e.g., biomarker or imaging), (c) health disparity studies, and (d) development of new technologies. (2) Epidemiologic and behavioral studies that do not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention. (3) Outcomes research and health services research that do not fit under the definition of clinical trial. Excluded from the definition of clinical research are in vitro studies that utilize human data or specimens that cannot be linked to a living individual and meet the requirements for exemption under 46.104(d)(4) of the Common Rule. The funding instrument for awards made under the program announcement will be grants (31 USC 6304). The anticipated direct costs budgeted for the entire period of performance for an FY24 KCRP Postdoctoral and Clinical Fellowship Award should not exceed $195,000. Refer to Section II.D.5, Funding Restrictions, for detailed funding information. Awards supported with FY24 funds will be made no later than September 30, 2025. The CDMRP expects to allot approximately $2.18M to fund approximately seven Postdoctoral and Clinical Fellowship Award applications. Funding of applications received is contingent upon the availability of federal funds for this program, the number of applications received, the quality and merit of the applications as evaluated by peer and programmatic review, and the requirements of the government. Funds to be obligated on any award resulting from this funding opportunity will be available for use for a limited time period based on the fiscal year of the funds. It is anticipated that awards made from this FY24 funding opportunity will be funded with FY24 funds, which will expire for use on September 30, 2030.

The NFRP Synergistic Idea Award supports new ideas that represent synergistic approaches to NF research involving two or three Principal Investigators (PIs). These investigators should utilize their complementary and synergistic perspectives to address a central problem or question in NF research. This award is designed to support both new and pre-existing partnerships and encourages participation of PIs from other research fields. Applications must include preliminary and/or published data that are relevant to NF and the proposed research project.

The NFRP Investigator-Initiated Research Award supports highly rigorous, high-impact research projects that have the potential to make an important contribution to NF research and/or patient care. Research projects may focus on any phase of research, excluding clinical trials. The rationale for a research idea may be derived from laboratory discovery, population-based studies, a clinicians firsthand knowledge of patients, or anecdotal data. Applications must include preliminary and/or published data that are relevant to NF and the proposed research project.

The NFRP Exploration - Hypothesis Development Award supports the initial exploration of innovative, high-risk, high-gain, and potentially groundbreaking concepts in NF research. Studies supported by this award mechanism are expected to lay the groundwork for future avenues of scientific investigation. The proposed research project should include a well-formulated, testable hypothesis based on strong scientific rationale and study design. The presentation of preliminary and/or published data is not required.

The Early Investigator Research Award supports NF-focused research opportunities for individuals in the early stages of their careers, under the guidance of a Designated Mentor. This opportunity allows for early-stage investigators to develop a research project, investigate a problem or question in NF research, and further their intellectual development as an NF researcher of the future. The postdoctoral investigator is considered the Principal Investigator (PI) of the application and must exhibit strong potential for, and commitment to, pursuing a career as an investigator at the forefront of NF research; however, the PI is not required to have previous NF research experience. Applications must include at least one mentor, appropriate to the proposed research project, who has experience in NF research and mentoring as demonstrated by a record of active funding, recent publications, and successful mentorship. The Designated Mentor can be a junior faculty member, in which case the PI is encouraged to include a co-mentor with a more robust track record in NF research and mentorship. The selected mentor(s) should also demonstrate a clear commitment to the development of the PI toward independence as an NF researcher.

This grant invites organizations and companies to collaborate on innovative health solutions aimed at reducing disease and mortality rates in low-and-middle-income countries.

The City of Arlington is accepting applications from public and non-profit agencies for projects that promote economic development and tourism in the City. Donor Name: City of Arlington State: County: All Counties Type of Grant: Grant Deadline: (mm/dd/yyyy) 06/28/2024 Size of the Grant: $100,000 to $500,000 Grant Duration: 1 Year Details: The funds can be used Qualifying events or projects; Tourism marketing  Marketing and operations of special events and festivals  Operations of tourism-related facilities owned by non-profit organizations  Operations and capital expenditures of tourism related facilities owned by municipalities Funding Information $175,000 is available for grants. Grant Period Funds are available on January 1, 2025, and must be spent by December 31, 2025. Who can apply? Open to any applicant that has a qualifying event or project All Applicants:  Completed Application Two letters of recommendation; each letter should explain the writer’s relationship to the project and/or sponsor, the writer’s qualifications for commenting on the project, and the writer’s opinion of the benefits of the proposed project. Copy of meeting minutes from the Board of Directors authorizing the submission of this application for Lodging Tax Funds. This does not apply to government agencies if the project/event is budgeted. A minimum 25% match (of total project costs) is required to be eligible to receive funding. Completed W-9. For more information, visit City of Arlington.

This program provides funding to U.S. Manufacturing Extension Partnership Centers to enhance manufacturing capabilities, workforce development, and supply chain resilience for small and medium-sized manufacturers.

This grant invites government, academic, and industry collaborators to propose innovative research projects that enhance air warfare and weapons technology for the Navy and Marine Corps.

This grant provides funding for researchers and organizations to develop and validate mathematical methods for assessing the performance of artificial intelligence systems, focusing on both theoretical foundations and practical applications using open-source models.

The "Solar Technologies Rapid Integration and Validation for Energy Systems (STRIVES)" grant aims to provide up to $31 million for projects that enhance power systems simulation software and develop new business models to better integrate and optimize various distributed energy resources like solar and wind generation, energy storage, and electric vehicles, thereby improving the operation and planning of a digitally controlled, decentralized electric grid.